Cargando…

Efficacy and Safety Study of Low-Molecular-Weight Heparin and Fondaparinux Sodium After Hip Arthroplasty: A Retrospective Cohort Study

BACKGROUND: Low molecular heparin(LMWH) and sodium sulfadiazine heparin(FPX) are commonly used to prevent deep vein thrombosis(DVT) after total hip arthroplasty(THA). In this study, we compared the role of these drugs in preventing DVT after THA. METHODS: Patients who underwent unilateral THA at the...

Descripción completa

Detalles Bibliográficos
Autores principales: Haibier, Abuduwupuer, Yusufu, Alimujiang, Lin, Hang, Kayierhan, Aiben, Abudukelimu, Yimuran, Abudurexiti, Tuerhongjiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10684995/
https://www.ncbi.nlm.nih.gov/pubmed/38033454
http://dx.doi.org/10.2147/ORR.S431372
_version_ 1785151532394610688
author Haibier, Abuduwupuer
Yusufu, Alimujiang
Lin, Hang
Kayierhan, Aiben
Abudukelimu, Yimuran
Abudurexiti, Tuerhongjiang
author_facet Haibier, Abuduwupuer
Yusufu, Alimujiang
Lin, Hang
Kayierhan, Aiben
Abudukelimu, Yimuran
Abudurexiti, Tuerhongjiang
author_sort Haibier, Abuduwupuer
collection PubMed
description BACKGROUND: Low molecular heparin(LMWH) and sodium sulfadiazine heparin(FPX) are commonly used to prevent deep vein thrombosis(DVT) after total hip arthroplasty(THA). In this study, we compared the role of these drugs in preventing DVT after THA. METHODS: Patients who underwent unilateral THA at the Sixth Affiliated Hospital of Xinjiang Medical University from April 2020 to December 2022 were retrospectively analyzed for inclusion in this study. According to the anticoagulant drugs used, the patients were divided into LMWH group (n=106) and FPX group (n=97). Changes in perioperative coagulation-related indices, hemoglobin, blood loss And the postoperative complications. RESULTS: The preoperative indexes of the two groups of patients, the difference was not statistically significant (P>0.05); the indexes of Intraoperative blood loss, Visible blood loss, Hidden blood loss, and Total blood loss of the two groups of patients were compared, and the difference was not significant (P>0.05); PT activity and INR in the LMWH group were significantly lower than those in the FPX group on the 1st and 5th postoperative days, and the differences were significant (P<0.05); Platelets, Hemoglobin, Hematocrit, D-dimer, and Fibrinogen were compared between the two groups on the 1st and 5th postoperative days, and the differences were not significant (P<0.05). The differences were not significant (P>0.05). The differences in blood transfusion rate and blood volume between the two groups were not significant (P>0.05); the total hospitalization cost of the LMWH group was significantly lower than that of the FPX group, and the difference was significant (P<0.05); and the differences in the incidence of postoperative complications between the two groups were not significant (P>0.05). CONCLUSION: In this study, we found that the efficacy and safety of FPX and LMWH in preventing VTE after THA were basically the same, and the total cost of hospitalization in the LMWH group was significantly lower than that in the FPX group; however, due to the limited inclusion of the sample size, high-quality, large-sample, long-term follow-up clinical studies are necessary.
format Online
Article
Text
id pubmed-10684995
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-106849952023-11-30 Efficacy and Safety Study of Low-Molecular-Weight Heparin and Fondaparinux Sodium After Hip Arthroplasty: A Retrospective Cohort Study Haibier, Abuduwupuer Yusufu, Alimujiang Lin, Hang Kayierhan, Aiben Abudukelimu, Yimuran Abudurexiti, Tuerhongjiang Orthop Res Rev Original Research BACKGROUND: Low molecular heparin(LMWH) and sodium sulfadiazine heparin(FPX) are commonly used to prevent deep vein thrombosis(DVT) after total hip arthroplasty(THA). In this study, we compared the role of these drugs in preventing DVT after THA. METHODS: Patients who underwent unilateral THA at the Sixth Affiliated Hospital of Xinjiang Medical University from April 2020 to December 2022 were retrospectively analyzed for inclusion in this study. According to the anticoagulant drugs used, the patients were divided into LMWH group (n=106) and FPX group (n=97). Changes in perioperative coagulation-related indices, hemoglobin, blood loss And the postoperative complications. RESULTS: The preoperative indexes of the two groups of patients, the difference was not statistically significant (P>0.05); the indexes of Intraoperative blood loss, Visible blood loss, Hidden blood loss, and Total blood loss of the two groups of patients were compared, and the difference was not significant (P>0.05); PT activity and INR in the LMWH group were significantly lower than those in the FPX group on the 1st and 5th postoperative days, and the differences were significant (P<0.05); Platelets, Hemoglobin, Hematocrit, D-dimer, and Fibrinogen were compared between the two groups on the 1st and 5th postoperative days, and the differences were not significant (P<0.05). The differences were not significant (P>0.05). The differences in blood transfusion rate and blood volume between the two groups were not significant (P>0.05); the total hospitalization cost of the LMWH group was significantly lower than that of the FPX group, and the difference was significant (P<0.05); and the differences in the incidence of postoperative complications between the two groups were not significant (P>0.05). CONCLUSION: In this study, we found that the efficacy and safety of FPX and LMWH in preventing VTE after THA were basically the same, and the total cost of hospitalization in the LMWH group was significantly lower than that in the FPX group; however, due to the limited inclusion of the sample size, high-quality, large-sample, long-term follow-up clinical studies are necessary. Dove 2023-11-24 /pmc/articles/PMC10684995/ /pubmed/38033454 http://dx.doi.org/10.2147/ORR.S431372 Text en © 2023 Haibier et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Haibier, Abuduwupuer
Yusufu, Alimujiang
Lin, Hang
Kayierhan, Aiben
Abudukelimu, Yimuran
Abudurexiti, Tuerhongjiang
Efficacy and Safety Study of Low-Molecular-Weight Heparin and Fondaparinux Sodium After Hip Arthroplasty: A Retrospective Cohort Study
title Efficacy and Safety Study of Low-Molecular-Weight Heparin and Fondaparinux Sodium After Hip Arthroplasty: A Retrospective Cohort Study
title_full Efficacy and Safety Study of Low-Molecular-Weight Heparin and Fondaparinux Sodium After Hip Arthroplasty: A Retrospective Cohort Study
title_fullStr Efficacy and Safety Study of Low-Molecular-Weight Heparin and Fondaparinux Sodium After Hip Arthroplasty: A Retrospective Cohort Study
title_full_unstemmed Efficacy and Safety Study of Low-Molecular-Weight Heparin and Fondaparinux Sodium After Hip Arthroplasty: A Retrospective Cohort Study
title_short Efficacy and Safety Study of Low-Molecular-Weight Heparin and Fondaparinux Sodium After Hip Arthroplasty: A Retrospective Cohort Study
title_sort efficacy and safety study of low-molecular-weight heparin and fondaparinux sodium after hip arthroplasty: a retrospective cohort study
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10684995/
https://www.ncbi.nlm.nih.gov/pubmed/38033454
http://dx.doi.org/10.2147/ORR.S431372
work_keys_str_mv AT haibierabuduwupuer efficacyandsafetystudyoflowmolecularweightheparinandfondaparinuxsodiumafterhiparthroplastyaretrospectivecohortstudy
AT yusufualimujiang efficacyandsafetystudyoflowmolecularweightheparinandfondaparinuxsodiumafterhiparthroplastyaretrospectivecohortstudy
AT linhang efficacyandsafetystudyoflowmolecularweightheparinandfondaparinuxsodiumafterhiparthroplastyaretrospectivecohortstudy
AT kayierhanaiben efficacyandsafetystudyoflowmolecularweightheparinandfondaparinuxsodiumafterhiparthroplastyaretrospectivecohortstudy
AT abudukelimuyimuran efficacyandsafetystudyoflowmolecularweightheparinandfondaparinuxsodiumafterhiparthroplastyaretrospectivecohortstudy
AT abudurexitituerhongjiang efficacyandsafetystudyoflowmolecularweightheparinandfondaparinuxsodiumafterhiparthroplastyaretrospectivecohortstudy